Curis, Inc. Share Price & Technical Analysis
CRIS · $0.50 (0.00%)
Healthcare / Biotechnology
$0.50
0.00%
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. T…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-17% return in May, -10% avg return in past 3 year May month.
-50% return in 2026, -29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | 22% | -45% | 0% | -17% | – | – | – | – | – | – | – | -50% |
| 25 | -10% | -9% | -30% | 0% | 14% | -8% | -26% | 0% | 0% | -6% | -12% | -29% | -117% |
| 24 | -22% | 3% | 7% | 41% | -33% | -35% | -21% | 0% | -2% | -20% | 0% | -31% | -113% |
| 23 | 33% | -17% | -3% | 51% | -9% | 8% | -2% | -30% | -41% | -28% | 198% | -15% | 144% |
| 22 | -34% | 6% | -29% | -62% | -18% | 18% | 3% | -5% | -27% | 13% | 1% | -30% | -164% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$21.69M
P/E ratio
—
52W high
$3.13
52W low
$0.46
Volume
45,071
Beta
3.06
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Curis, Inc. share price today?
- Curis, Inc. (CRIS) last traded around $0.50 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CRIS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CRIS. Download the app for real-time alerts.
- How can I analyze Curis, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.